These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28579455)

  • 1. Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae.
    Morozumi M; Okada T; Tajima T; Ubukata K; Iwata S
    Int J Antimicrob Agents; 2017 Aug; 50(2):255-257. PubMed ID: 28579455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children.
    Okada T; Morozumi M; Tajima T; Hasegawa M; Sakata H; Ohnari S; Chiba N; Iwata S; Ubukata K
    Clin Infect Dis; 2012 Dec; 55(12):1642-9. PubMed ID: 22972867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.
    Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Togashi T; Oba K; Morita K; Nagano N; Nakanishi M; Hara K; Hazama K; Watanabe T; Yamanaka T; Sasaki S; Furuyama H; Shibata M; Shida S; Ishizaka A; Tabata Y; Aoyagi H; Naito H; Yoshioka M; Horino A; Kenri T;
    PLoS One; 2017; 12(3):e0173635. PubMed ID: 28288170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.
    Waites KB; Ratliff A; Crabb DM; Xiao L; Qin X; Selvarangan R; Tang YW; Zheng X; Dien Bard J; Hong T; Prichard M; Brooks E; Dallas S; Duffy L; Mixon E; Fowler KB; Atkinson TP
    J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31484701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.
    Kawai Y; Miyashita N; Kubo M; Akaike H; Kato A; Nishizawa Y; Saito A; Kondo E; Teranishi H; Ogita S; Tanaka T; Kawasaki K; Nakano T; Terada K; Ouchi K
    Antimicrob Agents Chemother; 2013 May; 57(5):2252-8. PubMed ID: 23459497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure.
    Cheong KN; Chiu SS; Chan BW; To KK; Chan EL; Ho PL
    J Microbiol Immunol Infect; 2016 Feb; 49(1):127-30. PubMed ID: 25556047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase-shifting of the transmissibility of macrolide-sensitive and resistant Mycoplasma pneumoniae epidemics in Hong Kong, from 2015 to 2018.
    Zhao S; Musa SS; Qin J; He D
    Int J Infect Dis; 2019 Apr; 81():251-253. PubMed ID: 30822543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-generation tetracyclines for severe macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a retrospective analysis.
    Song X; Zhou N; Lu S; Gu C; Qiao X
    BMC Infect Dis; 2024 Oct; 24(1):1166. PubMed ID: 39407159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.
    Waites KB; Crabb DM; Duffy LB; Jensen JS; Liu Y; Paukner S
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009.
    Suzuki Y; Itagaki T; Seto J; Kaneko A; Abiko C; Mizuta K; Matsuzaki Y
    Pediatr Infect Dis J; 2013 Mar; 32(3):237-40. PubMed ID: 23114374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
    Wang YS; Zhou YL; Bai GN; Li SX; Xu D; Chen LN; Chen X; Dong XY; Fu HM; Fu Z; Hao CL; Hong JG; Liu EM; Liu HM; Lu XX; Luo ZX; Tang LF; Tian M; Yin Y; Zhang XB; Zhang JH; Zhang HL; Zhao DY; Zhao SY; Zhu GH; Zou YX; Lu Q; Zhang YY; Chen ZM
    World J Pediatr; 2024 Sep; 20(9):901-914. PubMed ID: 39143259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrolide-Resistant Mycoplasma pneumoniae, United States.
    Zheng X; Lee S; Selvarangan R; Qin X; Tang YW; Stiles J; Hong T; Todd K; Ratliff AE; Crabb DM; Xiao L; Atkinson TP; Waites KB
    Emerg Infect Dis; 2015 Aug; 21(8):1470-2. PubMed ID: 26196107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of Macrolide-Resistant Mycoplasma pneumoniae in Hong Kong Is Linked to Increasing Macrolide Resistance in Multilocus Variable-Number Tandem-Repeat Analysis Type 4-5-7-2.
    Ho PL; Law PY; Chan BW; Wong CW; To KK; Chiu SS; Cheng VC; Yam WC
    J Clin Microbiol; 2015 Nov; 53(11):3560-4. PubMed ID: 26338857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Clinical Features of Community-Acquired Pneumonia Caused by Macrolide-Resistant
    Choi JH; Seong GM; Ko Y; Kim YR; Kim C
    Microb Drug Resist; 2019 May; 25(4):577-581. PubMed ID: 30484744
    [No Abstract]   [Full Text] [Related]  

  • 15. Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008-2015.
    Tanaka T; Oishi T; Miyata I; Wakabayashi S; Kono M; Ono S; Kato A; Fukuda Y; Saito A; Kondo E; Teranishi H; Tanaka Y; Wakabayashi T; Akaike H; Ogita S; Ohno N; Nakano T; Terada K; Ouchi K
    Emerg Infect Dis; 2017 Oct; 23(10):1703-1706. PubMed ID: 28930026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrolide resistance of
    Jiang Y; Dou H; Xu B; Xu B; Zhou W; Wang H; Ge L; Hu Y; Han X; Qin X; Li J; Ye L; Wu L; Zuo H; Zhang Q; Liu L; Hu W; Shao J; Yin Q; Han L; Fu X; Dong X; Dong Y; Fu Y; Zhao M; Sun Q; Huo J; Liu D; Liu W; Li Y; Wang Y; Xin D; Shen K
    Epidemiol Infect; 2024 Apr; 152():e75. PubMed ID: 38634450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.
    Blondeau JM; Shebelski SD; Hesje CK
    Int J Antimicrob Agents; 2015 Jun; 45(6):594-9. PubMed ID: 25752567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China.
    Liu Y; Ye X; Zhang H; Xu X; Li W; Zhu D; Wang M
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):355-8. PubMed ID: 20638604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.
    Morozumi M; Hasegawa K; Kobayashi R; Inoue N; Iwata S; Kuroki H; Kawamura N; Nakayama E; Tajima T; Shimizu K; Ubukata K
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2302-6. PubMed ID: 15917525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of variables associated with prolonged admission duration in children with Mycoplasma pneumoniae pneumonia.
    Sung M; Roh EJ; Lee ES; Lee JY; Kim HB; Ahn Y; Eun BW; Kim JK; Kim HY; Jung SS; Kim M; Kang EK; Yang EA; Lee SJ; Park Y; Seo JH; Lee E; Yang ES; Cho HM; Shin M; Chung HL; Jang YY; Choi BS; Kim H; Jung JA; You ST; Lee MH; Kim JT; Kim BS; Hwang YH; Shim JY; Yang HJ; Han MY; Yew HY; Kim DH; Jeong SO; Whang K; Lee E; Jeon YH; Chung EH
    Clin Respir J; 2022 Nov; 16(11):756-767. PubMed ID: 36205104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.